Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer

The recombinant fusion protein aflibercept (ziv-aflibercept in the United States) binds VEGF-A, VEGF-B, and placental growth factor (PlGF). The monoclonal antibody bevacizumab binds VEGF-A. Recent studies hypothesized that dual targeting of VEGF/PlGF is more beneficial than targeting either ligand....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2014-06, Vol.13 (6), p.1636-1644
Hauptverfasser:	Chiron, Marielle, Bagley, Rebecca G, Pollard, Jack, Mankoo, Parminder K, Henry, Christophe, Vincent, Loïc, Geslin, Catherine, Baltes, Nina, Bergstrom, Donald A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Animals Antibodies, Monoclonal, Humanized - administration & dosage Bevacizumab Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Drug Synergism Female Humans Male Mice Middle Aged Molecular Targeted Therapy Placenta Growth Factor Pregnancy Proteins - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Vascular Endothelial Growth Factor A - antagonists & inhibitors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!